Treatment of Autosomal Dominant Polycystic Kidney Disease
Abstract
Autosomal dominant polycystic kidney disease is a systemic, hereditary disorder requiring life-long, multidisciplinary management. Approximately half of affected individuals progress to kidney failure by age 60 years. Recent advances in genetics, imaging, and disease pathophysiology have enabled earlier diagnosis and improved risk stratification and led to the development of disease-modifying therapies (such as tolvaptan) for high-risk patients. Despite the availability of comprehensive clinical practice guidelines, real-world implementation is hindered by disease heterogeneity, psychosocial impacts, and the need for individualized care. The aim of this narrative review is to facilitate guideline implementation by integrating evidence from patient perspectives and real-world effectiveness and offering strategies to overcome practical barriers.
Fields of Study & Subjects
Genetic and Kidney Cyst Diseases
Renal Diseases and Glomerulopathies
Renal and related cancers
Publication details
- Journal / source
- Journal of the American Society of Nephrology
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Volume
- 37
- Issue
- 6
- Pages
- 1319–1331
- Publication date
- 2 April 2026
- Language
- EN